The purpose of this study to see if the drug ruxolitinib with the drugs tacrolimus and methotrexate given before and following a peripheral blood stem cell transplant will prevent graft-versus-host disease (GVHD), a serious complication of a stem cell transplant, better than the drugs post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil.

Are you diagnosed with chronic graft versus host disease (cGVHD)? If so, you might be able to take part in a study to evaluate the safety and efficacy of belumosudil in combination with corticosteroids.

Do you have AML, ALL, or MDS, and are preparing for a stem cell transplant from an unrelated donor? If so, you might be able to take part in a study to will see if a reduced dose of a drug called cyclophosphamide will still reduce your chances of developing Graft versus Host disease, but also lower your chances of side effects from the drug.

We would like to learn about how people who apply for healthcare financial assistance experience the application process, including things that make the application process work well or that were challenging. At this time we are not able to offer interviews to people who applied to UNC or Duke, we are interested in hearing from people who applied to other programs (such as Atrium, Novant, Wake, Vidant, ECU, Cape Fear Health Net, Physicians Reach Out, or Project Access).

Have you been diagnosed with B-cell post-transplant lymphoproliferative disorder (PTLD) after an organ transplant? Have you not yet received any type of treatment for this condition? Then you may be eligible for a study to look at the safety and effectiveness of tafasitamab and rituximab combination treatment for PTLD.

Have you been listed for kidney transplant at UNC? If so, you may be able to take part in a research study to help us learn how the process of waiting for a kidney transplant impacts you.

Have you been infected with COVID-19? Are you a solid organ transplant recipient? Have you or your child received a COVID-19 vaccine or are planning to receive one? If so, you may be eligible to participate in a research study that will assess your immune response to COVID-19 infection or vaccination over a 5 year period. We are looking for children and adults aged 7-95 years, and plan to collect blood every 2-6 months over the study period. (Compensation provided for the first year).

The purpose of this study is to compare a usual maintenance treatment for multiple myeloma (lenalidomide) to using the study drug (daratumumab/rHuPH20) plus the usual treatment. We want to learn if the addition of daratumumab/rHuPH20 to the usual treatment could help you live longer after your stem cell transplant. This study will help the study doctors find out if this different approach is better than the usual approach.

We are collecting data on children living with chronic kidney disease, including children on dialysis or with a kidney transplant, to learn more about what happens over time. The data collected will be used for research projects.

To understand the relationship between biomarkers (found in the blood) and health outcomes among adults diagnosed with hepatocellular carcinoma who are receiving a liver transplant.